Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation

Teri B. Pearlstein, Gloria A. Bachmann, Howard A Zacur, Kimberly A. Yonkers

Research output: Contribution to journalArticle

Abstract

Purpose: This multicenter, double-blind, placebo-controlled crossover study evaluated the efficacy of a new oral contraceptive (OC) formulation containing drospirenone 3 mg and ethinyl estradiol (EE) 20 μg in treating symptoms of premenstrual dysphoric disorder (PMDD). Method: The OC formulation or placebo was administered for 24 days in a 28-day cycle (24/4), rather than the usual 21-day active treatment, 7-day inert-pill regimen. Participants (N=64) were randomized to either study treatment for three cycles and then after a washout period of one treatment-free cycle switched to the alternate treatment. Results: The mean decrease from baseline for total Daily Record of Severity of Problems (DRSP) scores while using drospirenone/EE was significantly greater than for placebo (-12.47, 95% CI=-18.28, -6.66; p

Original languageEnglish (US)
Pages (from-to)414-421
Number of pages8
JournalContraception
Volume72
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Oral Contraceptives
Ethinyl Estradiol
Placebos
Therapeutics
Cross-Over Studies
drospirenone
Premenstrual Dysphoric Disorder

Keywords

  • Drospirenone
  • Oral contraceptive
  • Premenstrual
  • Premenstrual dysphoric disorder
  • Selective serotonin reuptake inhibitor

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. / Pearlstein, Teri B.; Bachmann, Gloria A.; Zacur, Howard A; Yonkers, Kimberly A.

In: Contraception, Vol. 72, No. 6, 12.2005, p. 414-421.

Research output: Contribution to journalArticle

Pearlstein, Teri B. ; Bachmann, Gloria A. ; Zacur, Howard A ; Yonkers, Kimberly A. / Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. In: Contraception. 2005 ; Vol. 72, No. 6. pp. 414-421.
@article{e8bb529b995348ee902ee5392a235da3,
title = "Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation",
abstract = "Purpose: This multicenter, double-blind, placebo-controlled crossover study evaluated the efficacy of a new oral contraceptive (OC) formulation containing drospirenone 3 mg and ethinyl estradiol (EE) 20 μg in treating symptoms of premenstrual dysphoric disorder (PMDD). Method: The OC formulation or placebo was administered for 24 days in a 28-day cycle (24/4), rather than the usual 21-day active treatment, 7-day inert-pill regimen. Participants (N=64) were randomized to either study treatment for three cycles and then after a washout period of one treatment-free cycle switched to the alternate treatment. Results: The mean decrease from baseline for total Daily Record of Severity of Problems (DRSP) scores while using drospirenone/EE was significantly greater than for placebo (-12.47, 95{\%} CI=-18.28, -6.66; p",
keywords = "Drospirenone, Oral contraceptive, Premenstrual, Premenstrual dysphoric disorder, Selective serotonin reuptake inhibitor",
author = "Pearlstein, {Teri B.} and Bachmann, {Gloria A.} and Zacur, {Howard A} and Yonkers, {Kimberly A.}",
year = "2005",
month = "12",
doi = "10.1016/j.contraception.2005.08.021",
language = "English (US)",
volume = "72",
pages = "414--421",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation

AU - Pearlstein, Teri B.

AU - Bachmann, Gloria A.

AU - Zacur, Howard A

AU - Yonkers, Kimberly A.

PY - 2005/12

Y1 - 2005/12

N2 - Purpose: This multicenter, double-blind, placebo-controlled crossover study evaluated the efficacy of a new oral contraceptive (OC) formulation containing drospirenone 3 mg and ethinyl estradiol (EE) 20 μg in treating symptoms of premenstrual dysphoric disorder (PMDD). Method: The OC formulation or placebo was administered for 24 days in a 28-day cycle (24/4), rather than the usual 21-day active treatment, 7-day inert-pill regimen. Participants (N=64) were randomized to either study treatment for three cycles and then after a washout period of one treatment-free cycle switched to the alternate treatment. Results: The mean decrease from baseline for total Daily Record of Severity of Problems (DRSP) scores while using drospirenone/EE was significantly greater than for placebo (-12.47, 95% CI=-18.28, -6.66; p

AB - Purpose: This multicenter, double-blind, placebo-controlled crossover study evaluated the efficacy of a new oral contraceptive (OC) formulation containing drospirenone 3 mg and ethinyl estradiol (EE) 20 μg in treating symptoms of premenstrual dysphoric disorder (PMDD). Method: The OC formulation or placebo was administered for 24 days in a 28-day cycle (24/4), rather than the usual 21-day active treatment, 7-day inert-pill regimen. Participants (N=64) were randomized to either study treatment for three cycles and then after a washout period of one treatment-free cycle switched to the alternate treatment. Results: The mean decrease from baseline for total Daily Record of Severity of Problems (DRSP) scores while using drospirenone/EE was significantly greater than for placebo (-12.47, 95% CI=-18.28, -6.66; p

KW - Drospirenone

KW - Oral contraceptive

KW - Premenstrual

KW - Premenstrual dysphoric disorder

KW - Selective serotonin reuptake inhibitor

UR - http://www.scopus.com/inward/record.url?scp=27944495205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944495205&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2005.08.021

DO - 10.1016/j.contraception.2005.08.021

M3 - Article

VL - 72

SP - 414

EP - 421

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 6

ER -